Evidence map›Paper›PMID 30099580›Full record

ReviewWorld journal of urology2018

Genomics and clinical correlates of renal cell carcinoma.

Thomas J Mitchell, Sabrina H Rossi, Tobias Klatte, Grant D Stewart

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Oncometabolites in renal cancer.Nature reviews. Nephrology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas J MitchellCancer Genome Project, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK. tjm@sanger.ac.uk.ORCID http://orcid.org/0000-0003-0761-9503
Sabrina H RossiAcademic Urology Group, Department of Surgery, University of Cambridge, Cambridge, CB2 0QQ, UK.ORCID http://orcid.org/0000-0001-7048-7158
Tobias KlatteDepartment of Urology, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, BH7 7DW, UK.ORCID http://orcid.org/0000-0002-4392-6861
Grant D StewartAcademic Urology Group, Department of Surgery, University of Cambridge, Cambridge, CB2 0QQ, UK.ORCID http://orcid.org/0000-0003-3188-9140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClear cell, papillary cell, and chromophobe renal cell carcinomas (RCCs) have now been well characterised thanks to large collaborative projects such as The Cancer Genome Atlas (TCGA). Not only has knowledge of the genomic landscape helped inform the development of new drugs, it also promises to fine tune prognostication.

methodsA literature review was performed summarising the current knowledge on the genetic basis of RCC.

resultsThe Von Hippel-Lindau (VHL) tumour suppressor gene undergoes bi-allelic knockout in the vast majority of clear cell RCCs. The next most prevalent aberrations include a cohort of chromatin-modifying genes with diverse roles including PBRM1, SETD2, BAP1, and KMD5C. The most common non-clear cell renal cancers have also undergone genomic profiling and are characterised by distinct genomic landscapes. Many recurrent mutations have prognostic value and show promise in aiding decisions regarding treatment stratification. Intra-tumour heterogeneity appears to hamper the clinical applicability of sparsely sampled tumours. Ways to abrogate heterogeneity will be required to optimise the genomic classification of tumours.

conclusionThe somatic mutational landscape of the more common renal cancers is well known. Correlation with outcome needs to be more comprehensively furnished, particularly for small renal masses, rarer non-clear cell renal cancers, and for all tumours undergoing targeted therapy.

Indexed as

GenomicsCarcinoma, Renal CellDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHumansKidney NeoplasmsMutationNuclear ProteinsPTEN PhosphohydrolaseTelomeraseTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor ProteinsUbiquitin ThiolesteraseVon Hippel-Lindau Tumor Suppressor ProteinBAP1 protein, humanDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseNuclear ProteinsPBRM1 protein, humanPTEN PhosphohydrolasePTEN protein, humanSETD2 protein, humanTelomeraseTERT protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinEvolutionGenomicsMutationsPrognosisRenal cancerTherapy

Identifiers

PMID30099580
PMCPMC6280817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.